HK Stock Market Move | CHINA SHENGMU-PF (01432) rose more than 5%. In the first half of the year, it achieved a turnaround from loss to profit, and the sales proportion of its core product, organic milk, remained stable.

date
13:45 06/08/2026
avatar
GMT Eight
China Shengmu-PF (01432) rose more than 5%. As of the time of writing, it has increased by 3.95%, trading at HKD 0.395, with a transaction amount of HKD 1.0539 million.
CHINA SHENGMU-PF (01432) rose over 5%, and as of the time of reporting, it was up 3.95% at HKD 0.395, with a trading volume of HKD 1.0539 million. In terms of news, on August 5, CHINA SHENGMU-PF announced that in the first half of 2026, the group's main business performance continued to improve. Despite a significant decrease in one-time earnings such as government subsidies compared to the same period last year, it is still expected to achieve a profit of 15 million to 25 million yuan (the loss during the same period in 2025 was approximately 46 million yuan); the expected profit attributable to equity holders of the company is no less than 60 million yuan (the loss attributable to equity holders of the company was approximately 48 million yuan in the same period of 2025), thus achieving a turnaround from loss to profit. The announcement stated that the turnaround from loss to profit is mainly due to: a double-digit growth in fresh milk sales and a stable proportion of core product organic milk sales; steady improvement in the per cow milk yield, which has surpassed 13 tons for the first time, leading to a year-on-year decrease in the cost of milk sold per kilogram, with the decrease offsetting the pressure from falling raw milk prices, driving a year-on-year increase in overall gross profit margin; benefiting from the dual favorable factors of lower production costs and rising market prices for culling cows, the losses from changes in the fair value of dairy cows this period and losses from culling cows have decreased compared to the same period last year, resulting in a year-on-year decline in the losses from changes in the fair value of biological assets less selling expenses.